MegaGen has launched the ARi ExCon, an implant system engineered specifically for severely atrophic anterior ridges. By anchoring directly into basal cortical bone, the device achieves primary stability without requiring extensive alveolar bone volume restoration. The company rolled out the system in autumn 2024, and the first clinical results followed in early 2025.
What’s new
ARi stands for AnyRidge Incisor. ExCon denotes the External Conical implant-abutment connection. The system relies on two main components: a threaded body that grips dense basal cortical bone, and a smooth, machined Magic Cuff collar to support soft tissue in the supracrestal zone.
The underlying concept is straightforward. In severely resorbed anterior ridges, the alveolar bone is essentially gone. The basal cortical bone—the dense foundation layer—remains intact. ARi bypasses the missing alveolar bone entirely. Instead, it anchors directly into this basal structure using MegaGen’s proprietary KnifeThread design.
Dr. Kwang-Bum Park, MegaGen’s founder and the original creator of the AnyRidge concept, developed the system. ARi pushes the AnyRidge design philosophy into the most challenging clinical cases found in the esthetic zone.
Technical specs
| Parameter | Value |
|---|---|
| Full name | ARi ExCon (AnyRidge Incisor External Conical) |
| Diameters | 3.5 mm (standard); 4.2 mm, 4.75 mm (angled) |
| Thread lengths | 5.0, 7.0, 9.0 mm |
| Magic Cuff heights | 4, 6, 8 mm |
| Angles (angled version) | 12°, 20°, 30° |
| Connection | External Conical Hex (ExCon) |
| Abutment platforms | 3.8, 4.3, 4.8, 5.3, 5.8 mm |
| Material | Titanium |
| Surface | XPEED — calcium-incorporated nanostructure (CaTiO₃) |
| Thread design | KnifeThread (sharp, curved — minimizes shear stress) |
| Collar | Magic Cuff — smooth, machined |
| Regulatory status | FDA 510(k) K242030 |
The XPEED surface remains MegaGen’s flagship technology. Calcium ions form a CaTiO₃ nanostructure across the titanium surface, which activates osteoblasts and accelerates apatite formation. This promotes faster osseointegration, even when surrounding bone is scarce.
The two-part architecture tackles two distinct clinical hurdles simultaneously. The KnifeThread body secures basal bone stability, while the Magic Cuff collar provides necessary soft tissue support in the esthetic zone.
First clinical results
In May 2025, Park et al. published a case report in the Dentistry Journal (Basel, PMID 40559144). The paper detailed the use of ARi in two patients presenting with severely resorbed anterior ridges.
Surgeons placed 4.1 × 10.0 mm and 4.0 × 9.0 mm implants, achieving an insertion torque of 40 N/cm. The surgical protocol combined basal anchorage, a VIP flap, BCP grafting, and collagen membranes to manage bone contouring. At the two-year follow-up mark, peri-implant tissues remained stable and esthetic outcomes met clinical expectations.
One caveat accompanies these findings: the publication originates from MegaGen’s own team, including the company founder. Independent clinical studies are not yet available, placing the current evidence at level IV (case reports). ARi also does not completely eliminate the need for bone augmentation. Surgeons still relied on grafting for esthetic contouring in these initial cases.
BD Cuff — completing the system
Alongside ARi, MegaGen rolled out the BD Cuff (BlueDiamond Cuff), an implant tailored for thin posterior mandibular ridges. The mechanics mirror the ARi approach. A KnifeThread body anchors firmly in basal bone, while the Magic Cuff manages soft tissue without risking thread exposure.
The market response was rapid. Within three weeks of its pre-launch ahead of SIDEX 2024 in Seoul, more than 300 Korean clinics integrated the BD Cuff into their workflows. Paired together, ARi handles the anterior esthetic zone while BD Cuff manages the posterior, forming a unified system for patients facing generalized ridge atrophy.
Market context
A group of over 70 dentists founded South Korean implant manufacturer MegaGen in 2002. The company generated approximately 217.8 billion KRW (~$160 million) in 2023 revenue, marking a 30% year-on-year growth. Its portfolio spans over 1,400 implant-related products across five core systems: AnyRidge, AnyOne, BlueDiamond, ARi, and MiNi.
In November 2024, MegaGen acquired the American firm BIOLASE, a global leader in dental lasers known for its Waterlase technology. MegaGen secured the acquisition for $20 million following BIOLASE's bankruptcy proceedings, and Dr. Park stepped in as the new CEO. This strategic purchase grants MegaGen deeper access to the U.S. market and brings in-house laser technology that could shape its future implant designs.
In the broader market for atrophic ridge solutions, ARi faces several distinct clinical approaches:
| Method | Manufacturer | Characteristics |
|---|---|---|
| Zygomatic implants | Straumann, Nobel Biocare | Zygomatic bone anchorage, high surgical complexity |
| Short implants (4-6 mm) | Straumann BLX, Nobel Active | Minimal invasiveness, limited by bone height |
| All-on-4 / tilted implants | Nobel Biocare | Full-arch solution |
| GBR + standard implant | Various | Gold standard, adds 6-9 months |
| ARi (MegaGen) | MegaGen | Basal anchorage in esthetic zone, reduced GBR |
ARi targets a highly specific niche. The device is purpose-built for the anterior esthetic zone, a region where zygomatic implants are unviable and extensive GBR protocols typically add six months or more to the treatment timeline.
Relevance for CEE region
MegaGen operates a direct subsidiary in Poland. MegaGen Poland is headquartered at ul. Pańska 98/15 in Warsaw (contact: [email protected]). The manufacturer runs a dedicated Polish website (imegagen.com/pol/) and continues to expand its broader CEE distribution network, establishing offices in the Czech Republic (Puromed, Brno), Romania, and Moldova.
Korean implant makers, driven largely by MegaGen and Osstem, are capturing significant market share across the CEE region. They leverage competitive pricing structures against European premium brands like Straumann and Nobel Biocare. The ARi system could reinforce this momentum by delivering a viable alternative for complex cases that traditionally demanded costly, time-consuming GBR procedures.
For Polish implantologists, access to clinical training will dictate adoption. The basal anchorage technique demands specific surgical proficiencies. MegaGen operates an extensive global education programme, and the Warsaw office indicates that local training support is available.
The company has not publicly disclosed ARi ExCon pricing for the CEE market. Interested practitioners can reach out to MegaGen Poland directly ([email protected]).
FAQ
What is MegaGen ARi and how does it work?
ARi ExCon is an implant system engineered for severely atrophic anterior ridges. It anchors directly into basal cortical bone. The proprietary KnifeThread secures primary stability in this dense bone layer, while the smooth Magic Cuff collar manages the surrounding soft tissue. This dual-action design reduces the reliance on extensive GBR.
Does ARi completely eliminate the need for GBR?
Not entirely. While the implant draws its primary stability from basal bone, surgeons in published clinical cases still utilized bone augmentation to achieve proper esthetic contouring. ARi minimizes the overall scope of GBR but does not remove it from the esthetic zone workflow.
What is the evidence base for ARi?
Current literature includes one peer-reviewed publication featuring two case reports with a two-year follow-up (PMID 40559144), alongside a preprint case series. Both papers originate from the MegaGen team. Because the system is relatively new, no independent randomized studies exist yet.
Sources: MegaGen, PubMed — Park et al. 2025, MegaGen America, Dental Tribune